Regulating nicotine products

 Despite the harm caused by smoking, tobacco products are largely unregulated while medicinal nicotine used as an aid to stop smoking is very tightly controlled. Nicotine is the addictive element of tobacco but it is the tar and other toxins in tobacco smoke, not nicotine, that cause most of the harm. This section focuses on pure nicotine products such as nicotine replacement therapy and electronic cigarettes. For information on attempts to reduce the harm from tobacco products see the Regulating tobacco products page.

Tobacco harm reduction within a regulated framework, allowing smokers access to non-tobacco nicotine containing products, is supported by the UK government, most of the public health community, the MHRA and NICE. Such a regulated framework is currently in development and is due for publication by the MHRA in May 2013 at which time NICE guidance on tobacco harm reduction is also due for publication.

MHRA
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for assessing the safety, quality and efficacy of medicines, and authorising their sale or supply in the UK. In 2010, the MHRA held a public consultation on how best to regulate nicotine containing products.  A final decision on the regulation of these products is due in early 2013. 

NICE
The National Institute for health and Clinical Excellence (NICE) issues evidence-based guidance on the most effective ways to prevent, diagnose and treat disease and ill health. NICE is currently developing guidance on tobacco harm reduction.  This includes completely or partially substituting the nicotine from smoking with nicotine from less hazardous sources that do not contain tobacco such as pharmaceutical nicotine and electronic cigarettes either temporarily or indefinitely.  Products containing tobacco will not be covered by this guidance.

Department of Health Tobacco Plan
In the DH Tobacco Plan,  launched in March 2011, a commitment was made to “develop new approaches to encourage tobacco users who cannot quit to switch to safer sources of nicotine.”  This includes a commitment to co-ordinate, through the MHRA, scientific and market research on the use of nicotine-containing products, such as electronic cigaretttes, to inform decisions about the most effective and proportionate form of regulation. 

No documents here, yet.